Background: The incidence of type 2 diabetes mellitus (T2DM) is increasing in India. Left ventricular diastolic dysfunction (LVDD) is a complication of T2DM, which may develop irrespective of glycemic and hypertension control. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, e.g., empagliflozin and canagliflozin have been shown to reduce all-cause mortality including cardiovascular mortality in T2DM patients. Aims and objectives: The aims of this study were to evaluate the effect of canagliflozin on cardiac and renal parameters and improvement of LVDD at the end of 6 months in T2DM patients. Materials and methods: About 100 T2DM patients meeting inclusion and exclusion criteria were put on Canagliflozin (100 mg/day) and followed up for 6 months. Clinicodemographic profiles with blood pressure (BP) and body mass index (BMI) and fasting blood sugar, HbA1c, serum creatinine, eGFR, urine albumin/creatinine ratio (UACR) were assessed at baseline and 6 months. Also, echocardiographic parameters like average E/e’, septal and lateral e’ velocity, TR velocity and LA volume index (LAVI) were assessed and statistically analysis by SPSS 22.0 software. Results: Majority of patients were male (56%), aged between 45 and 60 years (57%), and obese (51%). Significant findings were, (1) Canagliflozin for 6 months improved E/A in 60 years and LAVI in <45 years’ age-group. (2) It improved LAVI in hypertensives and patients of <10 years of disease duration. (3) It improved serum creatinine and UACR.